Jarek Oleszczuk, country president of AstraZeneca Poland, the leading R&D investor in Poland, discusses the exciting milestones that the company has achieved, including reimbursement of two breakthrough oncology therapies, as well as the company’s addition of 500 staff, representing now a 1,150-strong workforce. Furthermore, he touches on AstraZeneca’s key role in catalysing the nation’s R&D revolution and the growing importance of the affiliate as it establishes itself as an important global hub for the company.
In the first 18 months as country president of AstraZeneca Poland, what have been your key milestones and achievements?
"Poland is the second largest country globally for AstraZeneca in regard to patient numbers and we are the leader in Poland, a very exciting time for us."
